Mixing Pfizer, AstraZ Covid-19 shots with Moderna gives better immune response: Study
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Saturday
January 28, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SATURDAY, JANUARY 28, 2023
Mixing Pfizer, AstraZ Covid-19 shots with Moderna gives better immune response: Study

Coronavirus chronicle

Reuters
07 December, 2021, 10:35 am
Last modified: 07 December, 2021, 10:44 am

Related News

  • European regulator recommends Pfizer's Omicron booster for children
  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose
  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • US foresees annual Covid boosters, just like flu: Officials
  • US donates 10 million more Pfizer Covid shots to Bangladesh

Mixing Pfizer, AstraZ Covid-19 shots with Moderna gives better immune response: Study

Reuters
07 December, 2021, 10:35 am
Last modified: 07 December, 2021, 10:44 am
Vials of coronavirus disease (Covid-19) vaccines of Pfizer-BioNTech and Moderna are seen in the town of Ricany near Prague, Czech Republic, February 25, 2021. REUTERS/David W Cerny/File Photo
Vials of coronavirus disease (Covid-19) vaccines of Pfizer-BioNTech and Moderna are seen in the town of Ricany near Prague, Czech Republic, February 25, 2021. REUTERS/David W Cerny/File Photo

A major British study into mixing Covid-19 vaccines has found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer-BioNTech shots followed by Moderna nine weeks later, according to the results on Monday.

"We found a really good immune response across the board..., in fact, higher than the threshold set by Oxford-AstraZeneca vaccine two doses," Matthew Snape, the Oxford professor behind the trial dubbed Com-COV2, told Reuters.

The findings supporting flexible dosing will offer some hope to poor and middle income countries that may need to combine different brands between first and second shots if supplies run low or become unstable.

"I think the data from this study will be especially interesting and valuable to low- and middle-income countries where they're still rolling out the first two doses of vaccines," Snape said.

"We're showing...you don't have to stick rigidly to receiving the same vaccine for a second dose...and that if the programme will be delivered more quickly by using multiple vaccines, then it is okay to do so."

If the AstraZeneca-Oxford vaccine is followed by a Moderna or Novavax shot, higher antibodies and T-cell responses were induced versus two doses of AstraZeneca-Oxford, according to researchers at the University of Oxford.

The study of 1,070 volunteers also found that a dose of the Pfizer-BioNTech , vaccine followed by a Moderna shot was better than two doses of the standard Pfizer-BioNTech course.

Pfizer-BioNTech followed by Novavax induced higher antibodies than the two-dose Oxford-AstraZeneca schedule, although this schedule induced lower antibody and T-cell responses than the two-dose Pfizer-BioNTech schedule.

No safety concerns were raised, according to the Oxford University study published in the Lancet medical journal.

Many countries have been deploying a mix and match well before robust data was available as nations were faced with soaring infection numbers, low supplies and slow immunisation over some safety concerns.

Longevity of protection offered by vaccines has been under scrutiny, with booster doses being considered as well amid surging cases. New variants, including Delta and Omicron, have now increased the pressure to speed up vaccination campaigns.

Blood samples from participants were tested against the Wild-Type, Beta and Delta variants, researchers of the Com-COV2 study said, adding that vaccines' efficacy against the variants had waned, but this was consistent across mixed courses.

Deploying vaccines using technology from different platforms - like Pfizer and Moderna's mRNA, AstraZeneca's viral vector and Novavax's protein-based shot - and within the same schedule is new.

The results may inform new approaches to immunisation against other diseases, he said.

The study also found that a first dose of the AstraZeneca-Oxford vaccine followed by any of the other candidates in the study generated a particularly robust response, consistent with findings in June.

The study was designed as a so-called "non-inferiority" study – the intent is to demonstrate that mixing is not substantially worse than the standard schedules - and compares the immune system responses to the gold-standard responses reported in previous clinical trials of each vaccine.

Top News

COVID vaccines / Covid-19 vaccines / Covid -19 vaccine / Pfizer coronavirus vaccine / Pfizer COVID vaccine / Pfizer Covid-19 Vaccine / Pfizer-19 Vaccine / AstraZeneca / AstraZeneca vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Bloomberg
    India state insurer doubles down on Adani amid short seller row
  • The Bombay blood type: A rare blood group in urgent need of database
    The Bombay blood type: A rare blood group in urgent need of database
  • Photo: TBS
    TBS Roundtable: What lies ahead in 2023

MOST VIEWED

  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent
  • Sean Bagley, 14, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    Updated Covid vaccines prevented illness from latest variants -CDC
  • People embrace at the international arrivals gate at Beijing Capital International Airport after China lifted the coronavirus disease (COVID-19) quarantine requirement for inbound travellers in Beijing, China January 8, 2023. REUTERS/Thomas Peter
    China says peak Covid infections exceeded 7 million daily, deaths more than 4,000 daily

Related News

  • European regulator recommends Pfizer's Omicron booster for children
  • Pfizer expects to hike US Covid vaccine price to $110-$130 per dose
  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • US foresees annual Covid boosters, just like flu: Officials
  • US donates 10 million more Pfizer Covid shots to Bangladesh

Features

Snipe in flight. Photo: Enam Ul Haque

Baikka Beel: 'A world where snipe work late'

1h | Panorama
Photo: Noor-A-Alam

Pet cafes: Where love for food and animals cohabit

3h | Food
Illustration: TBS

How MFS is turbocharging national economy

6h | Thoughts
Now is the time to focus on FDI composition

Now is the time to focus on FDI composition

8h | Panorama

More Videos from TBS

Gold covered mummy discovered in Egypt

Gold covered mummy discovered in Egypt

1h | TBS World
Kajol’s road paintings bring change in Gafargaon

Kajol’s road paintings bring change in Gafargaon

1d | TBS Stories
Carew & Company witnessed a remarkable growth

Carew & Company witnessed a remarkable growth

1d | TBS Stories
Gavi may have to leave Camp Nou

Gavi may have to leave Camp Nou

19h | TBS SPORTS

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Four top bankers arrested in DSA case filed by S Alam group 
Bangladesh

Four top bankers arrested in DSA case filed by S Alam group 

3
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

4
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

5
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net